Skip to main content
  • Saved

made a Post

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy

Source :

https://www.cfrjournal.com/articles/sodium-glucose-cotransporter-2-inhibitors-heart-failure-preserved-ejection-fraction

Until 2021, medical treatment of patients with heart failure (HF) and preserved ejection fraction (HFpEF) was mainly limited to diuretics to improve symptoms of HF, while no therapies demonstrated a mortality/morbidity benefit to these patients.1 True HFpEF has been found to have multiple pathophysiological causes.2 According to the 2021 European



Conclusion: The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I.